{"id":14337,"date":"2019-10-24T10:17:16","date_gmt":"2019-10-24T14:17:16","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14337"},"modified":"2019-10-24T10:17:16","modified_gmt":"2019-10-24T14:17:16","slug":"biogens-good-news-on-aducanumab-could-open-the-floodgates-for-alzheimers-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14337","title":{"rendered":"Biogen\u2019s good news on aducanumab could \u2018open the floodgates\u2019 for Alzheimer\u2019s drugs"},"content":{"rendered":"<p>(By Dennis J. Selkoe for ST<em>A<\/em>T)<\/p>\n<p>One of the many things I\u2019ve learned during four decades of doing research on Alzheimer\u2019s disease is that the work always brings surprises.\u00a0Biogen\u2019s announcement\u00a0on Tuesday about its experimental Alzheimer\u2019s drug, aducanumab, was a big one.\u00a0 Continue reading article<a href=\"https:\/\/www.statnews.com\/2019\/10\/23\/aducanumab-news-open-floodgates-alzheimers-drugs\/\"> here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Dennis J. Selkoe for STAT) One of the many things I\u2019ve learned during four decades of doing research on<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,15],"tags":[],"class_list":["post-14337","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14337"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14337\/revisions"}],"predecessor-version":[{"id":14338,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14337\/revisions\/14338"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}